AM580/NN
,/,
a/DT
stable/JJ
benzoic/JJ
derivative/NN
of/IN
retinoic/JJ
acid/NN
,/,
has/VBZ
powerful/JJ
and/CC
selective/JJ
cyto-differentiating/JJ
effects/NNS
on/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
cells/NNS
./.

All-trans/JJ
retinoic/JJ
acid/NN
(/(
ATRA/NN
)/)
is/VBZ
successfully/RB
used/VBN
in/IN
the/DT
cyto-differentiating/JJ
treatment/NN
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
./.
=====
Paradoxically/RB
,/,
APL/NN
cells/NNS
express/VBP
PML-RAR/NN
,/,
an/DT
aberrant/JJ
form/NN
of/IN
the/DT
retinoic/JJ
acid/NN
receptor/NN
type/NN
alpha/NN
(/(
RAR/NN
alpha/NN
)/)
derived/VBN
from/IN
the/DT
leukemia-specific/JJ
t(15;17)/NN
chromosomal/NN
translocation/NN
./.
=====
We/PRP
show/VBP
here/RB
that/IN
AM580/NN
,/,
a/DT
stable/JJ
retinobenzoic/JJ
derivative/NN
originally/RB
synthesized/VBN
as/IN
a/DT
RAR/NN
alpha/NN
agonist/NN
,/,
is/VBZ
a/DT
powerful/JJ
inducer/NN
of/IN
granulocytic/JJ
maturation/NN
in/IN
NB4/NN
,/,
an/DT
APL-derived/JJ
cell/NN
line/NN
,/,
and/CC
in/IN
freshly/RB
isolated/VBN
APL/NN
blasts/NNS
./.
=====
After/IN
treatment/NN
of/IN
APL/NN
cells/NNS
with/IN
AM580/NN
either/CC
alone/RB
or/CC
in/IN
combination/NN
with/IN
granulocyte/NN
colony-stimulating/JJ
factor/NN
(/(
G-CSF/NN
)/)
,/,
the/DT
compound/NN
induces/VBZ
granulocytic/JJ
maturation/NN
,/,
as/IN
assessed/VBN
by/IN
determination/NN
of/IN
the/DT
levels/NNS
of/IN
leukocyte/NN
alkaline/NN
phosphatase/NN
,/,
CD11b/NN
,/,
CD33/NN
,/,
and/CC
G-CSF/NN
receptor/NN
mRNA/NN
,/,
at/IN
concentrations/NNS
that/WDT
are/VBP
10-/CD
to/TO
100-fold/RB
lower/JJR
than/IN
those/DT
of/IN
ATRA/NN
necessary/JJ
to/TO
produce/VB
similar/JJ
effects/NNS
./.
=====
By/IN
contrast/NN
,/,
AM580/NN
is/VBZ
not/RB
effective/JJ
as/IN
ATRA/NN
in/IN
modulating/VBG
the/DT
expression/NN
of/IN
these/DT
differentiation/NN
markers/NNS
in/IN
the/DT
HL-60/NN
cell/NN
line/NN
and/CC
in/IN
freshly/RB
isolated/VBN
granulocytes/NNS
obtained/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
of/IN
chronic/JJ
myelogenous/JJ
leukemia/NN
patients/NNS
during/IN
the/DT
stable/JJ
phase/NN
of/IN
the/DT
disease/NN
./.
=====
In/IN
NB4/NN
cells/NNS
,/,
two/CD
other/JJ
synthetic/JJ
nonselective/JJ
RAR/NN
ligands/NNS
are/VBP
capable/JJ
of/IN
inducing/VBG
LAP/NN
as/RB
much/JJ
as/IN
AM580/NN
,/,
whereas/IN
RAR/NN
beta-/NN
or/CC
RAR/NN
gamma-specific/JJ
ligands/NNS
are/VBP
totally/RB
ineffective/JJ
./.
=====
These/DT
results/NNS
show/VBP
that/IN
AM580/NN
is/VBZ
more/RBR
powerful/JJ
than/IN
ATRA/NN
in/IN
modulating/VBG
the/DT
expression/NN
of/IN
differentiation/NN
antigens/NNS
only/RB
in/IN
cells/NNS
in/IN
which/WDT
PML-RAR/NN
is/VBZ
present/JJ
./.
=====
Binding/NN
experiments/NNS
,/,
using/VBG
COS-7/NN
cells/NNS
transiently/RB
transfected/VBN
with/IN
PML-RAR/NN
and/CC
the/DT
normal/JJ
RAR/NN
alpha/NN
,/,
show/VBP
that/IN
AM580/NN
has/VBZ
a/DT
lower/JJR
affinity/NN
than/IN
ATRA/NN
for/IN
both/DT
receptors/NNS
./.
=====
However/RB
,/,
in/IN
the/DT
presence/NN
of/IN
PML-RAR/NN
,/,
the/DT
synthetic/JJ
retinoid/NN
is/VBZ
a/DT
much/RB
better/JJR
transactivator/NN
of/IN
retinoic/JJ
acid-responsive/JJ
element-containing/JJ
promoters/NNS
than/IN
the/DT
natural/JJ
retinoid/NN
,/,
whereas/IN
,/,
in/IN
the/DT
presence/NN
of/IN
RAR/NN
alpha/NN
,/,
AM580/NN
and/CC
ATRA/NN
have/VBP
similar/JJ
activity/NN
./.
=====
This/DT
may/MD
explain/VB
the/DT
strong/JJ
cyto-differentiating/JJ
potential/NN
of/IN
AM580/NN
in/IN
PML-RAR-containing/JJ
leukemic/JJ
cells/NNS
./.